outcomes of children under 3 treated with tisagenlecleucel for b-all
Published 3 years ago • 85 plays • Length 3:40Download video MP4
Download video MP3
Similar videos
-
1:35
outcomes of allosct following blinatumomab in children and young adults with r/r b-all
-
1:22
diagnostics and treatment outcomes from primary cbcl
-
8:57
outcomes of sct in t-all and t-lbl
-
1:32
genomic sequencing as a driver of advancements in pediatric hematology
-
2:24
comparing allosct outcomes in secondary and de-novo acute lymphoblastic leukemia
-
2:12
results from a phase i trial of tinostamustine in patients with r/r classical hl
-
1:20
impact of tp53 mutations on outcomes in myelofibrosis
-
0:49
the future of pediatric clinical trials
-
0:42
upcoming trial updates in all
-
1:30
a phase i trial investigating a novel oral flt3 inhibitor, bmf-500, in flt3-mutant aml
-
1:12
the value of flt3 inhibitors in aml and focus for future trial designs
-
1:18
celestial-tncll: ongoing phase iii study of sonrotoclax zanubrutinib vs ven obi for tn cll
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
2:05
pregnancy outcomes after hsct during childhood
-
1:54
covalent-103: investigating bmf-500, an oral covalent flt3 inhibitor, in acute leukemias
-
1:43
extended follow-up of the alpine trial: superior outcomes with zanubrutinib in r/r cll/sll
-
2:44
the tk008 phase iii trial on using donor lymphoctyes to treat patients with high-risk acute leukemia
-
2:43
gemtuzumab ozogamicin in frontline aml therapy